Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6491224 | 0.98 | KMT2A (0.39) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL476505 | 0.93 | KDM4E (0.44) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL5200159 | 0.90 | KMT2A (0.37) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL6502877 | 0.88 | KMT2A (0.36) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL28209374 | 0.87 | KDM4E (0.39) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL8913521 | 0.86 | KDM4E (0.35) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL4496703 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL17560417 | 0.85 | KDM4E (0.38) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL476374 | 0.84 | KMT2A (0.40) | KDM4EKMT2AGABRA1TSHRGABRG2 | |
| SCHEMBL15568164 | 0.81 | ALOX5 (0.31) | KMT2ATSHRPMP22EPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100422160-C | Morpholine derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2008-10-01 | — | — | CN | disclosed |
| EP-1150970-B1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2007-08-22 | — | — | EP | disclosed |
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| CN-1353698-A | Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives | SANOFI SYNTHELABO (FR) | 2002-06-12 | — | — | CN | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150970-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Sanofi-Aventis (FR) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000047572-A1 | (1-PHENACY-3-PHENYL-3-PIPERIDYLETHYL)PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2000-08-17 | — | — | WO | disclosed |